Valuation: Moderna, Inc.

Market Cap 27.09B 23.68B 21.9B 20.1B 38.04B 2,611B 38.7B 261B 103B 1,275B 102B 99.51B 4,401B P/E 2026 *
-7.88x
P/E 2027 * -14.4x
Enterprise Value 23.69B 20.7B 19.15B 17.57B 33.25B 2,282B 33.83B 228B 89.7B 1,115B 88.95B 87B 3,848B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 9.81x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-7.26%
1 week-17.52%
Current month-9.82%
1 month+13.99%
3 months+15.49%
6 months+50.97%
Current year+114.14%
1 week 62.8
Extreme 62.8
76.72
1 month 54.51
Extreme 54.51
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Free

Director

14,766 0.0037%
05/07/26 Free

Executive/Senior Manager

57,022 0.0144%
02/07/26 Fiscal year

Chief Financial Officer

3,607 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-7.51%-17.52%+96.97%-48.49% 27.09B
+2.18%+1.65%+23.91%-5.91% 67.6B
+0.85%-4.42%+39.25%+199.67% 51.32B
+0.94%+39.60%+39.60%+39.60% 42.97B
+0.16%-1.89%-51.35%-53.27% 40.81B
+5.92%+5.03%+62.63%-24.96% 29.12B
+1.36%-1.58%+68.50%+90.98% 22.99B
-2.94%+9.28%+9.66%+190.29% 21.55B
+2.15%-1.61%+58.33%+129.01% 16.38B
-2.86%-10.95%+70.49%+150.62% 16.2B
Average +0.04%-0.43%+41.80%+66.75% 33.6B
Weighted average by Cap. +0.50%-1.02%+34.43%+53.81%

Financials

2026 *2027 *
Net sales 2.1B 1.83B 1.69B 1.55B 2.94B 202B 2.99B 20.2B 7.93B 98.58B 7.87B 7.69B 340B 2.55B 2.23B 2.06B 1.89B 3.58B 246B 3.64B 24.6B 9.66B 120B 9.58B 9.37B 415B
Net income -3.41B -2.98B -2.76B -2.53B -4.79B -329B -4.87B -32.87B -12.91B -160B -12.8B -12.52B -554B -1.85B -1.62B -1.49B -1.37B -2.6B -178B -2.64B -17.83B -7B -87.01B -6.94B -6.79B -300B
Net Debt -3.41B -2.98B -2.75B -2.53B -4.78B -328B -4.86B -32.84B -12.9B -160B -12.79B -12.51B -553B -2.05B -1.79B -1.66B -1.52B -2.88B -198B -2.93B -19.79B -7.78B -96.61B -7.71B -7.54B -334B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
16/07/26 US$63.15 -7.51% 5,584,949
15/07/26 US$68.28 +1.25% 3,427,825
14/07/26 US$67.44 +0.64% 5,812,332
13/07/26 US$67.01 -1.85% 8,521,959
10/07/26 US$68.27 -10.83% 9,176,930
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
68.28USD
Average target price
48.26USD
Spread / Average Target
-29.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock